Development and validation an HPLC-UV method for determination of esomeprazole and pirfenidone simultaneously in rat plasma: application to a drug monitoring study

Basit Öğe Kaydı
dc.authoridDural, Emrah/0000-0002-9320-8008
dc.contributor.authorDural, Emrah
dc.contributor.authorKoz, Sema Tulay
dc.contributor.authorKoz, Suleyman
dc.date.accessioned2024-10-26T18:00:19Z
dc.date.available2024-10-26T18:00:19Z
dc.date.issued2021
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractBackground and Aims: It has been observed that the combined treatment of esomeprazole and pirfenidone provides increased efficacy in the treatment of pulmonary fibrosis disease, recently. The aim of this study is to develop a simple, sensitive, and reliable high-performance liquid chromatography method to be used in drug monitoring to increase the effectiveness of esomeprazole and pirfenidone in treatment and to reduce their adverse effects. Methods: Separation was conducted with a C18 reverse-phase column (4.6 mm x 250 mm, 5 mu m) used as a mobile phase prepared with the phosphate buffer (10 mM KH2PO4 and 10 mM K2HPO4) and acetonitrile (60:40, v/v) by an isocratic flow (1 mL/min). Mobile phase pH was adjusted to 3.0. Ultraviolet detection was accomplished at 305 nm. The column oven was held at 35 degrees C to ensure an efficient analytical separation. Results: Analytical recovery of esomeprazole was between 92.43 and 105.36% and for pirfenidone it was found between 89.56 and 104.32%. Accuracy values of esomeprazole and pirfenidone were determined between (-2.90) - 4.22 and (-4.45) - 5.78, respectively. Precision (RSD%) was <= 7.89. The quantification limit was determined as 0.58 and 0.36 ng/mL. Plasma esomeprazole and pirfenidone levels were found as 0.87-8296.87 ng/mL (612.99 +/- 2212.20, mean +/- standard deviation) and 0.45-238.60 ng/mL (61.44 +/- 76.35, mean +/- standard deviation), respectively. Conclusion: Unexpectedly high RSD values were observed in both plasma (360.88%) and dose-rated results (89.61%) of esomeprazole, and pirfenidone were thought to be related to individual metabolism differences.
dc.description.sponsorshipScientific Research Projects Support Programme of Sivas Cumhuriyet University (CUBAP) [T-684]
dc.description.sponsorshipThis research was supported by The Scientific Research Projects Support Programme of Sivas Cumhuriyet University (CUBAP) under project number T-684.
dc.identifier.doi10.26650/IstanbulJPharm.2020.0091
dc.identifier.endpage25
dc.identifier.issn2587-2087
dc.identifier.issue1
dc.identifier.startpage16
dc.identifier.trdizinid456106
dc.identifier.urihttps://doi.org/10.26650/IstanbulJPharm.2020.0091
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/456106
dc.identifier.urihttps://hdl.handle.net/20.500.12418/27638
dc.identifier.volume51
dc.identifier.wosWOS:000655270400003
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherIstanbul Univ, Fac Pharmacy
dc.relation.ispartofIstanbul Journal of Pharmacy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectEsomeprazole
dc.subjectpirfenidone
dc.subjectrat plasma
dc.subjectmethod validation
dc.subjectHPLC-UV
dc.titleDevelopment and validation an HPLC-UV method for determination of esomeprazole and pirfenidone simultaneously in rat plasma: application to a drug monitoring study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu